Study 123ABC 
==============

***The schedule and checklists for the study.***

**Author:** *Mike Vogel CRC Manager*

[toc]

# Schedule


## Study Timeline Table
| Visit Name              | Alternative Name | Phase     | Window (-) | Day/Date | Window (+) |
| :---------------------- | :--------------- | :-------- | :--------- | :------- | :--------- |
| ICF (1A)                |                  | Screening | 0          | -56      | 0          |
| Screening (1B/1C)       |                  | Screening | 1          | -55      | 1          |
| BAE (2A)                |                  | Screening | 0          | -20      | 0          |
| BAE (2B)                |                  | Screening | 0          | -6       | 6          |
| Randomization (3A)      |                  | Treatment | 0          | 1        | 0          |
| Dose Admin (3A)         |                  | Treatment | 2          | 29       | 2          |
| Dose Admin (3B)         |                  | Treatment | 2          | 57       | 2          |
| Dose Admin (3C)         |                  | Treatment | 2          | 85       | 2          |
| Dose Admin (3D)         |                  | Treatment | 2          | 113      | 2          |
| Dose Admin (3E)         |                  | Treatment | 2          | 141      | 2          |
| PAC1 (4A)               |                  | Treatment | 2          | 169      | 2          |
| Dose admin/PAC1 (3F/4B) |                  | Treatment | 2          | 197      | 2          |
| Dose admin/PAC1 (3G/4C) |                  | Treatment | 2          | 197      | 2          |
| Dose admin/PAC1 (3G/4C) |                  | Treatment | 2          | 197      | 2          |
| Dose admin/PAC1 (3H/4D) |                  | Treatment | 2          | 197      | 2          |
| Dose Admin (3G)         |                  | Treatment | 2          | 225      | 2          |
| Dose Admin (3H)         |                  | Treatment | 2          | 253      | 2          |
| End of dose (3I)        |                  | Treatment | 2          | 281      | 2          |
| PAC2 (4C)               |                  | Treatment | 2          | 316      | 2          |
| PAC2 (4D)               |                  | Treatment | 2          | 330      | 2          |
| PAC3 (4E)               |                  | Treatment | 2          | 407      | 2          |
| PAC3 (4F)               |                  | Treatment | 2          | 421      | 2          |
| Follow up (5)           |                  | Treatment | 5          | 421      | 5          |



## Chart

[View the interactive chart of the schedule](../timeline.html)

---

# Checklist

## Task: Informed Consent
The purpose of this task is to obtain informed consent from the patient. This will involve discussing the study with them, then an internal medical discussion to determine their eligibility to move forward.

### Step 1 - Obtain Informed Consent
- [ ] Explain the study details, including purpose, procedures, risks, and benefits to the patient
- [ ] Obtain informed consent from the patient, ensuring they understand and agree to the study terms
- [ ] [Optional] Discuss with the patient about the possibility of using their data for future research

#### REFERENCES
- Protocol - Consent Definition
- Protocol - Inclusion/Exclusion Criteria
- Consent Form
- Guidance on Research Use of Data

#### PEOPLE
- Patricia Bellweather (Patient Recruiter) email: pbellweather@mail.com phone: 509.555.3419

### Step 2 - Record Consent Decision
- [ ] File the signed consent form in the patients clinical study folder
- [ ] Scan the signed consent form into the EHR system
- [ ] Record the signed consent into the EDC system

#### REFERENCES

- Record Keeping Guidelines
- Epic EHR (Robot Script Available)
- Medidata EDC (Robot Script Available)

### Step 3 - Inform Internal Medical Personnel

- [ ] Email Patricia with the result of the consent
- [ ] Inform Rachel and Mark about the patient consent

#### PEOPLE
- Patricia Bellweather (Patient Recruiter) email: pbellweather@mail.com phone: 509.555.3419
- Rachel Auchliff (Site Rater) email: rauchliffe@mail.com phone: 957.555.2323
- Mark Davis (Clinical Trial Administrator) email: mdavis@mail.com
---